Story content courtesy of B3C Newswire, DE
The project is addressing the development of T-Track® MS as a novel blood-based diagnostic test supporting the initial diagnosis of multiple sclerosis (MS) and enabling the monitoring of MS disease progression. This new project is to last for about two years with a funding of > 350.000 EUR proportionally supplied by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.
Lophius Biosciences is a leading developer of innovative T cell based diagnostic test systems. One of the company’s platform technologies, the “Reverse T Cell Technology (RTT)”, represents a novel strategy for the diagnosis of T cell-mediated diseases. Due to the high specificity of RTT for activated Th cells, the intended use of the RTT assay is the reliable detection of disease-specific activated Th cells as a novel biomarker for the diagnosis and monitoring of ongoing autoimmune diseases such as MS.
Initial data from a collaboration between Lophius Biosciences and the Clinic and Policlinic for Neurology, University of Regensburg, and the Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, demonstrated preliminary clinical proof of principle for this MS test.